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Purpose: A high rate of response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) has been observed in certain patients (women, of East Asian ethnicity, with non-smoking history and
adenocarcinoma histology) with mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR. Some cases of
high-grade neuroendocrine carcinoma of the lung harboring mutations have been sporadically reported.
Methods: We describe the case of a 78-year-old woman with large-cell neuroendocrine carcinoma of the lung,
with mutation in exon 21 L858R and co-expression of adenocarcinoma markers.
Results: A mass (3.0 cm in diameter) was identified in the inferior lobe of the left lung, accompanied by metastases
into ipsilateral mediastinal lymph nodes and elevations of serum pro-gastrin-releasing peptide and
carcinoembryonic antigen. Initial transbronchial brushing cytology suggested high-grade neuroendocrine carcinoma
favoring small-cell carcinoma in poorly smeared and degenerated preparations, and revealed exon 21 L858R mutation.
Re-enlargement of the cancer and bone metastases was observed after chemotherapy, and further testing suggested
large-cell neuroendocrine carcinoma with immunoreactivity to markers of primary lung adenocarcinoma and L858R
mutation. High-grade neuroendocrine carcinoma with mutations in the tyrosine kinase domain of EGFR may be
associated with adenocarcinoma, as reviewed from the literature and may also apply to our case.
Conclusions: EGFR-TKI could provide better quality of life and survival in patients with advanced or relapsed
high-grade neuroendocrine carcinoma with EGFR gene mutations. Further studies in this respect are warranted.
Keywords: Epidermal growth factor receptor, Gene mutation, Large-cell neuroendocrine carcinoma, Lung cancer,
Small-cell carcinoma, Tyrosine kinase inhibitorBackground
The entry of tyrosine kinase inhibitors (TKIs) gefitinib
(Iressa®, AstraZeneca, Wilmington, Delaware) and erlotinib
(Tarceva®, Genentech, South San Francisco, California),
which target epidermal growth factor receptor (EGFR), is
one of the most recent, gratifying events in the treatment
of advanced non-small-cell lung cancer (NSCLC). Clinical
trials have revealed significant variability in response to* Correspondence: sakaiyasuhiro@gaia.eonet.ne.jp
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reproduction in any medium, provided the orEGFR-TKIs, and patient characteristics such as sex, dom-
inantly female, East Asian ethnicity, non-smoking history,
and adenocarcinoma (ADC) histology have been associated
with an increased likelihood of EGFR-TKI effectiveness
[1-7]. Furthermore, a high response rate (60 to 90%) to
treatment with EGFR-TKIs has been observed in patients
harboring mutations in exons 18 to 21 of the tyrosine
kinase domain of EGFR, with exon 19 deletions and
exon 21 L858R point mutations comprising about
90% of all mutations [8,9]. Although the mechanism
of lethal interstitial pneumonia as a side effect of
EGFR-TKI is still unknown, EGFR-TKI can be strikingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in patients with advanced NSCLC harboring EGFR
gene mutations. Currently, EGFR-TKI is considered
third-line chemotherapy for patients with inoperable
and recurrent NSCLC after first-line platinum-based com-
bination chemotherapy and second-line chemotherapy
with docetaxel; however, in future the combination of
cytotoxic agents and EGFR-TKI may become first- or
second-line standard chemotherapy. According to the
statement of the International Association for the Study
of Lung Cancer/American Thoracic Society/European
Respiratory Society about lung ADC [10], EGFR gene
mutation should be routinely examined in all patients
with NSCLC before nonsurgical treatment and after
the initiation of EGFR-TKI therapy, with a view of
predicting reactivity and resistance to EGFR-TKI, if
possible, with the use of Kirsten rat sarcoma virus
oncogene homolog (KRAS) mutation and anaplastic
lymphoma kinase (ALK) rearrangement [11-16].
Interestingly, case reports of small-cell lung carcinoma
(SCLC) harboring EGFR gene mutation and apparently
responding to EGFR-TKI have sporadically appeared
since 2005 [17-27]. The mechanism by which SCLC
acquires EGFR gene mutation is still unknown, but such
cases may occur in association with ADC. Moreover,
a few cases of large-cell neuroendocrine carcinoma
(LCNEC) with EGFR gene mutations have recently
been identified [28-30], an additional case of which is
described here.
Case presentation
A 78-year-old Japanese woman ex-smoker (half a pack per
day) with past histories of pulmonary tuberculosis and
uterine leiomyoma had been under medical treatment
for chronic heart failure with atrial fibrillation, unstable
angina, eosinophilic myocarditis, bronchial asthma, hyper-
uricemia, hyperlipidemia, and hypothyroidism. At a
follow-up examination one and half year earlier, chest
computed tomography showed a mass (1.5 cm in diam-
eter) in the inferior lobe of the left lung. It had doubled
in size within the following four months, and positron
emission tomography (PET) and magnetic resonance im-
aging (MRI) revealed metastases to ipsilateral mediastinal
lymph nodes. Serum tumor markers were as follows:
pro-gastrin-releasing peptide 105 pg/ml (standard range
0 – 80), carcinoembryonic antigen (CEA) 21.8 ng/ml
(0 – 5.2), and cytokeratin 19 fragment 3.0 ng/ml (0 – 2).
Transbronchial brushing and needle aspiration against the
tumor demonstrated small cells with a high nuclear/
cytoplasm ratio and fine granular nuclear chromatin
scattered around a large cell cluster in poorly smeared
Papanicolaou stains, suggesting high-grade neuroendo-
crine carcinoma favoring small-cell carcinoma (Figure 1,
upper panels). EGFR L858R mutation was detected inexon 21 (PNA LNA PCR-Clamp method) of another
brushing and aspiration specimen. The patient received
four cycles of systemic chemotherapy with carboplatin
(area under curve 5) and etoposide (80 mg/m2) for three
months, at the end of which the size of the tumor de-
creased by one half. Lumbago developed after six months,
and metastases to the left iliac bone and the femur were
detected by MRI. Focal radiotherapy (39Gy/13Fr) was car-
ried out. The primary lesion had doubled again during the
following four months with enlargement of mediastinal
lymph nodes. Histopathologic and cytologic follow up
examinations were carried out: Papanicolaou smears
revealed cells larger than those at previous examina-
tions, and numerous scattered sheet-like arrange-
ments. The cells had fine granular nuclear chromatin
and prominent large nucleoli of a high nuclear/cytoplasm
ratio and relatively rich cytoplasm (Figure 1, lower panels).
Transbronchial lung biopsy failed to provide detailed
histology of the tumor cells because of insufficient
sampling volume, and proliferative patterns such as
organoid structures and nuclear molding could not
be identified. Immunohistochemical analysis showed
tumor cell immunoreactivity to three neuroendocrine
markers: chromogranin A, synaptophysin, and CD56
(Figure 2). Retrospectively, the cells subject of the
second examination showed almost the same morph-
ology as that of cells of the first test regardless of
artifactual degeneration. Consequently, the tumor was
diagnosed as large-cell neuroendocrine carcinoma. Thy-
roid transcription factor-1 was diffusely and strongly posi-
tive in the cells. Interestingly, CEA and Napsin A were
also focally positive. It is noteworthy that the mutation-
specific immunostaining for the detection of EGFR exon
21 L858R mutation (rabbit monoclonal antibody, 1:100,
clone 43B2, Cell Signaling Technology®, Danvers, MA)
was positive (Figure 2). Second-line chemotherapy is
under consideration at present.
Discussion
With the present case we aim to demonstrate a possible
additional case of LCNEC with EGFR gene mutation.
Three other cases have been reported retrospectively
(Table 1), and although no clinicopathologic feature has
been identified in them, two have occurred in non-
smokers, two show EGFR gene exon 19 deletion muta-
tion, and one demonstrates exon 18 point mutation
[28-30]. Ours may be the first in an ex-smoker with
LCNEC harboring exon 21 L858R point mutation. The
mechanism and significance of EGFR gene mutation in
LCNEC is still unknown. Nonetheless, twenty cases of
SCLC with EGFR gene mutation have been reported and
are used in this discussion (Table 1) [18-27]. Among
these SCLC cases, the ratio of male: female is 1:3 (age
60.9 ± 26.1 years; range, 36 – 89), and of smoker: non-
Figure 1 Papanicolaou smears from the first examination diagnosed as high-grade neuroendocrine carcinoma favoring small-cell
carcinoma (upper panels left to right: ×200, ×400), and the second examination diagnosed as large-cell neuroendocrine carcinoma
(lower panels: ×200, ×400).
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SCLC and adenocarcinoma, or suggest a transformation
from adenocarcinoma to SCLC; eleven display EGFR
gene exon 19 deletion mutation, and eight exon 21 L858R
point mutation proportionally similar to mutations inFigure 2 Histopathologic stains from the second transbronchial biops
synaptophysin, CD56; lower panels: carcinoembryonic antigen, thyroid tran
mutation (×400).adenocarcinoma. Whether LCNEC with EGFR gene
mutation is related to adenocarcinoma is still unknown,
although only one case has suggested transformation from
adenocarcinoma to LCNEC [30]. The present case was,
however, immunoreactive to adenocarcinoma markersy. Upper panels left to right: hematoxylin and eosin, chromogranin A,
scription factor-1, Napsin A, epidermal growth factor receptor L858R
Table 1 Review of epidermal growth factor receptor gene mutation in patients with high-grade neuroendocrine
carcinoma and its combination with other types
Authors Age Gender Smoking Stage Cell type Specimen Activating EGFR mutation
Okamoto et al. (2006) 72 F No IV SCLC biopsy exon 19, del E746-A750
Zakowski et al. (2006) 45 F No IV ADC → SCLC biopsy exon 19, del L747-P753insQ
Morinaga et al. (2007) 46 F No IIIB ADC → SCLC biopsy exon 19, del E746-A750
Fukui et al. (2007) 62 F No IIIB combined SCLC and ADC resection exon 21, L858R mutaion
Tatematsu et al. (2008) 36 F No IV combined SCLC and ADC resection exon 21, L858R mutaion
81 M Yes IV SCLC biopsy exon 18, G719A point mutation
69 M Yes IA combined SCLC and ADC biopsy exon 21, L858R mutaion
89 F Yes IB SCLC biopsy exon 21, L858R mutaion
65 M Yes IIA combined SCLC and ADC resection exon 19, 15-bp deletion
Alam et al. (2010) 73 F No IV ADC (lung), SCLC (liver) biopsy exon 21, L858R mutaion
Shiao et al. (2011) 63 M Yes III SCLC biopsy exon 19 deletion (del E746-S752 insV)
54 F No II - III SCLC biopsy exon 19 deletion (del E746-A750)
Sequist et al. (2011) 67 F NA NA ADC → SCLC biopsy exon 21, L858R mutaion
54 F NA NA ADC → SCLC biopsy exon 19 deletion
56 F NA IV ADC → SCLC biopsy exon 21, L858R mutaion
40 F NA NA ADC → SCLC biopsy exon 19 deletion
61 F NA NA ADC → SCLC biopsy exon 21, L858R mutaion
Iyoda et al. (2011) NA NA NA NA LCNEC resection exon 18, codon 725 (ACG to ACA)
De Pas et al. (2011) 66 M No IV LCNEC biopsy exon 19 deletion (p.L747_A755>AT)
Yanagisawa et al. (2012) 46 M No IIIA ADC → LCNEC resection→ biopsy exon 19 micro-deletion
Lu et al. (2012) 61 M Yes IIA combined SCLC and SQCC resection exon 19, del E746-A750 (K745 AAA)
62 F No IIIA combined SCLC and ADC resection exon 19, del E746-A750 (K745 AAA)
Lu et al. (2012) 62 F No IIIA combined SCLC and ADC resection exon 19 mutation, codon 746-754
Our case (2012) 78 F Yes (Ex) IV LCNEC brushing exon 21, L858R mutaion
ADC, adenocarcinoma; EGFR, epidermal growth factor receptor, F, female; LCNEC, large-cell neuroendocrine carcinoma; M, male; NA, not available; SCLC,
small-cell lung cancer; SQCC, squamous cell carcinoma.
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alveolar cells, which was a conspicuous finding when con-
sidering the occurrence of LCNEC with EGFR gene
mutation.
Distinctly, the detection of EGFR exon 21 L858R mu-
tation by PCR on the first specimen might have been
due to the very few adenocarcinoma cells, combined
type with adenocarcinoma. Adenocarcinoma might have
been present before the development of LCNEC and be-
fore the first biopsy. It can be assumed that the present
case was consistently adenocarcinoma with neuroendo-
crine differentiation harboring EGFR exon 21 L858R
mutation. Neuroendocrine proliferative patterns, such as
organoid ones and nuclear molding, were not identified
in the whole section of the surgical specimen. Also, the
clonal relation between the first and second tests was
not clear because the mutational status of the EGFR
gene in the second biopsy was not addressed by PCR.
Nonetheless, this case might be consistently LCNEC
harboring EGFR exon 21 L858R mutation, especiallythat the cytologic features displayed by both tests were
almost the same, noting specially the PCR conducted on
the same tumor cells as those of the Papanicolaou prep-
arations, and the positivity of EGFR exon 21 L858R
mutation-specific immunostaining in the second biopsy.
Indeed, high-grade neuroendocrine carcinoma harboring
EGFR gene mutation may have molecular adenocarcino-
matous characteristics, at least by derivation from the
literature about cases like the present one. Further stud-
ies are needed on the occurrence of high-grade neuroen-
docrine carcinoma harboring EGFR gene mutation.
An additional therapeutic choice for high-grade neuro-
endocrine carcinoma showing poor prognosis is expected,
and EGFR-TKI that is now available commercially should
naturally be considered even for this carcinoma, much
more than for one with adenocarcinomatous characteris-
tics. Presently there is no regimen of chemotherapy for
high-grade neuroendocrine carcinoma harboring EGFR
gene mutation. Nonetheless, the detection of this disease
needs to be attempted through further study. The
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presence of EGFR gene mutation, as opposed to resistance
mutation such as that of exon 20 T790M, exon 19 D761Y,
and exon 21T854A [11,31,32]. Testing for the presence of
EGFR gene mutation by PCR in SCLC and LCNEC may,
however, be practically difficult from the aspect of cost
and rarity. Immunohistochemistry may be one of the
strategies for easy detection of EGFR gene mutation.
Available and noteworthy are two mutation-specific
antibodies for the detection of EGFR gene mutations:
anti-EGFR exon 19 E746-750 deletion antibody (rabbit
monoclonal, clone 6B6, Cell Signaling Technology®,
Danvers, MA) along with anti-EGFR exon 21 L858R
mutation antibody [33,34]. Anti-EGFR exon 21 L858R
mutation-specific immunostaining of lung adenocar-
cinoma demonstrates excellent sensitivity (95.2%) and
specificity (98.8%), although the former may react to
exon 19 deletion overlapping E746-A750. Immuno-
staining with these antibodies is less costly and easier
to conduct than by molecular detection of EGFR gene
mutation, covers the two major patterns of EGFR gene
mutation, and can be used for SCLC and LCNEC in which
EGFR gene mutation is less frequent than in ADC.
Conclusions
The fact that patients with lung cancer have as many
therapeutic choices as possible is gratifying. High-grade
neuroendocrine carcinoma generally shows more ag-
gressiveness and rapid relapse than NSCLC. Interest-
ingly, our case suggests the presence of high-grade
neuroendocrine carcinoma harboring EGFR gene muta-
tion: EGFR-TKI may provide better quality of life and sur-
vival in patients with advanced or relapsed high-grade
neuroendocrine carcinoma, particularly that with EGFR
gene mutation. EGFR gene mutation-specific immuno-
staining is potentially effective and should be utilized for
easy detection and further study of this rare disease.
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